I am interested in the identification of cancer stem cells in lung squamous cell carcinoma and targeting of these stem cells in preclinical chemotherapeutic trials.
Publications
Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris J, Clambey ET, Thurman JM, Nemenoff RA. Complement activation via a C3a receptor pathway alters CD4 T lymphocytes and mediates lung cancer progression. Cancer Res. 2017 Nov 8. [Epub ahead of print] PubMed PMID: 29118090
Barón AE, Kako S, Feser WJ, Malinowski H, Merrick D, Garg K, Malkoski S, Pretzel S, Siegfried JM, Franklin WA, Miller Y, Wolf HJ, Varella-Garcia M. Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol. 2017 Oct;12(10):1512-1523. PubMed PMID: 28634123
Mansoori JN, Little N, Malkoski SP. Maximizing Benefits and Minimizing Harms of Lung Cancer Screening: A Teachable Moment. JAMA Intern Med. 2017 Aug 1;177(8):1197-1198. PubMed PMID: 28628709
Ziemke M, Patil T, Nolan K, Tippimanchai D, Malkoski SP. Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer. 2017 Jul;109:28-35. PubMed PMID: 28577946
Du L, Chen X, Cao Y, Lu L, Zhang F, Bornstein S, Li Y, Owens P, Malkoski S, Said S, Jin F, Kulesz-Martin M, Gross N, Wang XJ, Lu SL. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFß signaling. Oncogene. 2016 Sep 1;35(35):4641-52. PubMed PMID: 26876212
Haeger SM, Thompson JJ, Kalra S, Cleaver TG, Merrick D, Wang XJ, Malkoski SP. Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. Oncogene. 2015 Apr 20. [Epub ahead of print] PubMed PMID: 25893305
MacLaren R, Preslaski CR, Mueller SW, Kiser TH, Fish DN, Lavelle JC, Malkoski SP. A randomized, double-blind pilot study of dexmedetomidine versus midazolam for intensive care unit sedation: patient recall of their experiences and short-term psychological outcomes. J Intensive Care Med. 2015 Mar;30(3):167-75. PubMed PMID: 24227448
Mueller SW, Preslaski CR, Kiser TH, Fish DN, Lavelle JC, Malkoski SP, MacLaren R. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med. 2014 May;42(5):1131-9. PubMed PMID: 24351375
Malkoski SP, Cleaver TG, Thompson JJ, Sutton WP, Haeger SM, Rodriguez KJ, Lu SL, Merrick D, Wang XJ. Role of PTEN in basal cell derived lung carcinogenesis. Mol Carcinog. 2014 Oct;53(10):841-6. PubMed PMID: 23625632
Mueller SW, Preslaski CR, Kiser TH, Fish DN, Lavelle JC, Malkoski SP, Maclaren R. A Randomized, Double-Blind, Placebo-Controlled Dose Range Study of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal. Crit Care Med. 2013 Dec 17. [Epub ahead of print] PubMed PMID: 24351375
Maclaren R, Preslaski CR, Mueller SW, Kiser TH, Fish DN, Lavelle JC, Malkoski SP. A Randomized, Double-Blind Pilot Study of Dexmedetomidine Versus Midazolam for Intensive Care Unit Sedation: Patient Recall of Their Experiences and Short-Term Psychological Outcomes. J Intensive Care Med. 2013 Nov 12. [Epub ahead of print] PubMed PMID: 24227448
Malkoski SP, Cleaver TG, Thompson JJ, Sutton WP, Haeger SM, Rodriguez KJ, Lu SL, Merrick D, Wang XJ. Role of PTEN in Basal Cell Derived Lung Carcinogenesis. Mol Carcinog. 2013 Apr 26. [Epub ahead of print] PubMed PMID: 23625632